About ERIX
EiRx Therapeutics is a specialist provider of pre-clinical therapeutics to the pharmaceutical industry. Our unique scientific expertise and knowledge in the field of Apoptosis provide a sound base to discover and develop new medicines that will safely and selectively repair this natural process in disease. The potential benefits from these new medicines are enormous, since as many as 70% of all human disease have some defect in the control of Apoptosis.
Apoptosis - the biological process that determines whether cells in our bodies live or die...
http://www.eirx.com/index.html

Purchased some of these on the strength of the PROGRESS UPDATE looks promising.
http://moneyam.uk-wire.com/cgi-bin/articles/200603200701130254A.html

ERX interview with John Pool
http://www.wallstreetreporter.com/interview.php?id=18589&player=real
Latest News
CANCER COLLABORATION WITH BIOMERIEUX SA
http://moneyam.uk-wire.com/cgi-bin/articles/200607120700230534G.html
Biomerieux Web Site
http://www.biomerieux.com/servlet/srt/bio/portail/home
ABOUT ERX Focus Of The Month
http://www.billamag.net/focus-document-text.asp?FocusTextID=1
ERX pdf filehttp://www.eirx.com/eirx_heading_images/Yokohama2005.pdf
19/09/2006 A 50% reduction in breast tumour volume size seen with Eirx lead molecule in animal studies
http://moneyam.uk-wire.com/cgi-bin/articles/200609190700171175J.html

Past and present collaborative partners include:

* bioMieux SA
* Almac Diagnostics Ltd
* Merck & Co, Ltd
* Biofocus plc
* MGI Pharmaceuticals, Inc
* OSI Pharmaceuticals, Inc
* Sareum plc
* Regen Therapeutics plc
* SR Pharma plc

its your last chance to top up now!!!

I can't find the connection only that survivin is mentioned in the pdf file in the header, having said that if mike says there is one, there may be.

Finds known targets (e.g. aurora, survivin, PKC)

http://www.eirx.com/eirx_heading_images/Yokohama2005.pdf

Also here.

As little as 5 years ago cancer was still thought of largely in terms of a proliferative disease. In contrast, EiRx has built its discovery model around what has now become established dogma; namely that cancer cells critically require a block on the induction of apoptosis. Experiments have shown that proliferative stimuli alone, such as overexpression of the oncogene cMyc, rapidly trigger apoptosis and elimination of the cell. In this context, induction of apoptosis can be seen as a safety mechanism. Blockade of apoptosis can occur through dysregulation of apoptosis effectors such as p53 or from an increase in a survival signals, such as upregulation of discrete genes (e.g. survivin and bcl2) or from the up regulation of an entire survival pathway (e.g. PI3K/AKT).

The charts below illustrates example results from these assays. Survivin and aurora, both of which were identified using ALIBI, represent control genes. Extensive data generated for all kinase, GPCR and other enzyme targets demonstrates direct functional modulation of apoptosis and cancer cell death, from both long term clonagenicity and molecular apoptosis assays. Induction of apoptosis and cell death for many targets compares well with siRNA specific to survivin and aurora controls

http://www.billamag.net/focus-text-main-quoted.asp?FocusTextID=33

there is, its been confirmed by phone by mike if you go over to the dark side

I stand by my post 732.

PH - Your post 735 in response has again NOTHING TO DO WITH EIRx.

Driver - I'm not sure what your handle is on this little tete-a-tete. I'm not denying that EIRx have patents involving the use of Survivin, I'm just questioning PH's implication of a tie-up with Eli Lilly (something that he still refuses to provide evidence for).

I just checked mikes post; he didnt say there was a connection he said, Survivin does connect back to ERX which is a different thing.

But PH never lets the facts spoil a good story. ;-)

LOL

he rang the company according to him on the darkside

latest over-hyped ramped dog

zscrooge

We are trying not to ramp ERX on this thread, only after the facts. The right deal or some milestone payments from the companies below will see ERX a multi bagger with out any ramping.


4 licensed to OSI Pharmaceuticals (oncology)
- compound library screening approach
- up to $18.8 M in upfront and milestones


5 in collaborative drug discovery with Sareum (all fields)
- structure-based rational drug design strategy
- develop to Phase I/II

Can I smell something?

I smell news..

Yes pothead, have been over and had a read ! we will see :)

I smell news..

I smell Bull.

I smell news..

Luckypicker - 12 Dec'06 - 12:07 - 14953 of 14956


"john"
12/12/2006 11:53
To
XXX

Subject
Re: Shareholder Question





Hi
As CEO as just returned from the US completing statements
J
------------------
Sent with Instant Email from T-Mobile

-----Original Message-----
From: XXXX
Date: Tue, 12 Dec 2006 11:51:22
To:"John K Pool"
Subject: Re: Shareholder Question

Dear John

why no RNS??






Presenting it like this would've helped - nice find though.- I believe this is worthy of RNS

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
ABOUT LY2181308 AND SURVIVIN
LY2181308 targets survivin, a molecule that supports the survival of
cells that would normally die through programmed cell death or apoptosis.
Survivin helps in the abnormal growth of cancer cells, and is abundant in
many types of cancers, including colon, brain, lung, skin and others, but
nearly nonexistent in normal cells and tissues.

------------------------------------------------------------------------------------------------------------
-

http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/12-11-2006/0004488564&EDATE=
7 SURVIVIN in my patents list
Inventor: HAYES IAN (IE); COTTER TOM (IE); (+5) Applicant: EIRX THERAPEUTICS LTD (IE); HAYES IAN (IE); (+6)
EC: C07K14/47A1A; C07K14/47A33 IPC: C07K14/47; A61K38/00; C07K14/435 (+2)
Publication info: WO03091384 - 2003-11-06

------------------------------------------------------------------------------------------------------------
-
CARLSBAD, Calif., Dec. 11 /PRNewswire-FirstCall/ -- Isis
Pharmaceuticals, Inc. (Nasdaq: ISIS) announced today that Eli Lilly and
Company (NYSE: LLY) highlighted two antisense oligonucleotide (ASO) drugs
in its "Update to Wall Street on Strategic Priorities and Pipeline
Progress" on Thursday. Advances with both survivin ASO (LY2181308) and
eIF-4E ASO (LY2275796) drugs were singled out among Select Early- to
Mid-Stage Pipeline Developments. Based on promising activity in early
studies, Lilly said that it is initiating Phase 2 trials for survivin ASO
in a broad range of cancers including liver cancer, prostate cancer, acute
myelogenous leukemia, ovarian cancer and non-small cell lung cancer; the
first of these trials is planned to begin this month. Lilly also said that
the Phase 1 development program for eIF-4E ASO is progressing well.
"We are pleased that Lilly includes our collaboration drugs among its
selected strategic priorities," commented C. Frank Bennett, Ph.D., Isis'
Senior Vice President of Research. "These drugs resulted from our
productive collaboration and Lilly's broad investment in antisense
technologies. We continue to work together and hope that additional drugs
will arise from our collective efforts. Lilly's progress with these
anti-cancer drugs emphasizes the broad therapeutic potential of Isis'
platform antisense technologies, and underscores our strategy of working
with partners to expand the scope of our development pipeline.





Kind regards

More bull.

Re: Try chilling Croyde 1
The Old Dog,

I am with you on your no news theory, as I also dont want things to be rushed and what reassures me is that I know they will not be. It remains a case of our patience will be rewarded.

I had a quick conversation with JP earlier today. Did not want to speak for too long as he was with CT who had just returned from the US. They were finalising the results RNS and I think that we may see it on Thursday/Friday but from I can tell they are not holding back for any sinister reason. If anything it still looks like they may have been looking to add something to the chairmans statement or notes on post balance sheet transactions. Anyway, we will know soon enough now.

Regards,

Croyde

:)